Join to View Full Profile
9120 Double Diamond PkwyReno, NV 89521
Dr. Palumbo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Joseph Palumbo, MD, is a psychiatrist based in Reno, NV, who completed his medical education at the George Washington University School of Medicine and Health Sciences in 1985. He currently serves as the Chief Medical Officer at BioVie, a position he has held since 2021, and previously held the same role at Zynerba Pharmaceuticals from 2019 to 2021. Dr. Palumbo has contributed to publications on various topics, including the effects of cannabidiol treatment in fragile X syndrome and clinical trial designs in amyotrophic lateral sclerosis, some of which have been cited multiple times in other works. Additionally, he is involved in a clinical trial evaluating BIV201 for patients with cirrhosis and refractory ascites.
Education & Training
George Washington University School of Medicine and Health SciencesClass of 1985, MD
Certifications & Licensure
PA State Medical License 1995 - 2022
CT State Medical License 1995 - 1998
NY State Medical License 1989 - 1998
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites Start of enrollment: 2021 Jun 17
- A Study of NE3107 in Early Parkinson's Start of enrollment: 2025 Mar 26
Publications & Presentations
PubMed
- 1 citationsPotential augmentation of terlipressin antidiuretic effects by gabapentinoids.Penelope N Markham, Jasmohan S Bajaj, Paul J Thuluvath, David Koch, Joseph Palumbo
Journal of Hepatology. 2024-08-01 - 1 citationsA phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias.Jonathan Haroon, Kaya Jordan, Kennedy Mahdavi, Elisabeth Rindner, Sergio Becerra
Medicine. 2024-07-26 - 12 citationsRole of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment.Joseph M Palumbo, Brian F Thomas, Dejan Budimirovic, Steven Siegel, Flora Tassone
Journal of Neurodevelopmental Disorders. 2023-01-09
Press Mentions
BioVie : Regulation FD Presentation - Form 8-KJuly 5th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
